View Company News: See Articles

AGI Therapeutics, based in Ireland, was established in 2003 by a group of experienced senior industry executives who have a successful track record in developing pharmaceutical products for all major global markets over the past 20 years.

AGI Therapeutics is focused on developing new improved drug therapies for gastrointestinal diseases and disorders. The company applies its KME™ development model to identify existing drugs or ‘known molecular entities’ with established safety profiles which can be developed and clinically differentiated for gastrointestinal indications.

The KME™ development model allows the company to more quickly establish the efficacy profile of its candidates for the target gastrointestinal indications.

AGI Therapeutics is listed on the London Stock Exchange's Alternative Investment Market.